X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-09-22 | MLYS | Mineralys Therapeutics, Inc. | Slingsby Brian Taylor | Dir | S - Sale | $28.81 | -104,320 | 7,805,718 | -1% | -$3,005,303 | ||||||
| DM | 2026-09-22 | OMER | Omeros Corp | Borges David J. | VP, Finance, CAO | S - Sale+OE | $20.95 | -20,000 | 0 | -100% | -$419,000 | |||||
2026-09-22 | TNGX | Tango Therapeutics, Inc. | Newcomb Jessica | Principal Accounting Officer | S - Sale | $24.22 | -8,200 | 59,121 | -12% | -$198,613 | ||||||
| M | 2026-09-22 | SKYE | Skye Bioscience, Inc. | Schwab Andrew J. | Dir, 10% | S - Sale | $1.62 | -148,079 | 981,269 | -13% | -$239,555 | |||||
| D | 2026-09-23 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $491.57 | -9,500 | 668,728 | -1% | -$4,669,918 | |||||
| M | 2026-09-22 | SKYE | Skye Bioscience, Inc. | 5Am Partners Vii, LLC | 10% | S - Sale | $1.62 | -148,079 | 981,269 | -13% | -$239,555 | |||||
2026-09-22 | RPRX | Royalty Pharma Plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $58.53 | -100,000 | 293,601 | -25% | -$5,853,095 | ||||||
2026-09-23 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $39.17 | -2,210 | 559,225 | 0% | -$86,565 | ||||||
| D | 2026-09-23 | AKTS | Aktis Oncology, Inc. | Czibere Akos | Chief Medical Officer | S - Sale+OE | $20.69 | -12,500 | 0 | -100% | -$258,621 | |||||
2026-09-22 | ANL | Adlai Nortye Group Ltd. | Ji Ping | Dir | S - Sale | $16.63 | -5,000 | 131,667 | -4% | -$83,150 | ||||||
| D | 2026-09-22 | PHVS | Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus | Dir | S - Sale+OE | $36.19 | -800 | 115,167 | -1% | -$28,952 | |||||
2026-09-21 | VSTM | Verastem, Inc. | Calkins Daniel | CFO | S - Sale | $7.70 | -55 | 118,014 | 0% | -$424 | ||||||
| M | 2026-09-21 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.10 | +15,089 | 2,855,318 | +1% | +$31,687 | |||||
2026-09-21 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, EVP, Treasurer | S - Sale | $25.00 | -4,139 | 168,707 | -2% | -$103,475 | ||||||
2026-09-21 | OKUR | Onkure Therapeutics, Inc. | Saccomano Nicholas A | Pres, CEO | S - Sale | $2.97 | -87 | 11,160 | -1% | -$259 | ||||||
2026-09-21 | OKUR | Onkure Therapeutics, Inc. | Leverone Jason A. | CFO | S - Sale | $2.97 | -302 | 18,500 | -2% | -$898 | ||||||
| D | 2026-09-22 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $494.83 | -9,500 | 668,728 | -1% | -$4,700,851 | |||||
2026-09-21 | LEGN | Legend Biotech Corp | Santos Carlos E | CFO | S - Sale | $9.14 | -5,430 | 14,246 | -28% | -$49,630 | ||||||
2026-09-22 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $1.03 | +2,000 | 364,871 | +1% | +$2,058 | ||||||
2026-09-21 | PHVS | Pharvaris N.V. | Nassif David W. | CFO , CLO | S - Sale | $36.47 | -6,000 | 113,800 | -5% | -$218,801 | ||||||
| D | 2026-09-21 | MLYS | Mineralys Therapeutics, Inc. | Warren Eric | Chief Commercial Officer | S - Sale+OE | $28.12 | -7,438 | 38,400 | -16% | -$209,136 | |||||
| D | 2026-09-22 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $68.29 | -3,500 | 153,902 | -2% | -$239,015 | |||||
| D | 2026-09-18 | TEVA | Teva Pharmaceutical Industries Ltd | Savage Brian | Interim GC | S - Sale+OE | $38.85 | -7,342 | 8,500 | -46% | -$285,215 | |||||
2026-09-22 | BFRG | Bullfrog Ai Holdings, Inc. | Blacher Joshua | CFO | P - Purchase | $0.53 | +50,000 | 65,000 | +333% | +$26,425 | ||||||
2026-09-22 | BFRG | Bullfrog Ai Holdings, Inc. | Singh Vininder | CEO, 10% | P - Purchase | $0.60 | +75,000 | 2,442,446 | +3% | +$44,918 | ||||||
| D | 2026-09-21 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $494.56 | -9,500 | 668,728 | -1% | -$4,698,271 | |||||
2026-09-18 | TEVA | Teva Pharmaceutical Industries Ltd | Mignone Roberto | Dir | S - Sale | $39.06 | -367,600 | 119,807 | -75% | -$14,356,802 | ||||||
2026-09-22 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +10,100 | 1,056,800 | +1% | +$455 | ||||||
2026-09-17 | SION | Sionna Therapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $6.33 | -3,448,811 | 6,456,234 | -35% | -$21,835,018 | ||||||
2026-09-17 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $69.08 | -10,000 | 5,057,460 | 0% | -$690,847 | ||||||
| M | 2026-09-16 | BOLT | Bolt Biotherapeutics, Inc. | Yonehiro Grant | COO | S - Sale | $3.32 | -13,176 | 17,269 | -43% | -$43,807 | |||||
2026-06-05 | BOLT | Bolt Biotherapeutics, Inc. | Nemec Sarah | SVP, Finance, PAO | P - Purchase | $3.88 | +509 | 17,082 | +3% | +$1,973 | ||||||
| M | 2026-09-16 | BOLT | Bolt Biotherapeutics, Inc. | Nemec Sarah | SVP, Finance, PAO | S - Sale | $3.32 | -7,842 | 17,082 | -31% | -$26,072 | |||||
2026-06-05 | BOLT | Bolt Biotherapeutics, Inc. | Quinn William P. | Pres, CEO, CFO | P - Purchase | $3.88 | +637 | 25,384 | +3% | +$2,469 | ||||||
| M | 2026-09-16 | BOLT | Bolt Biotherapeutics, Inc. | Quinn William P. | Pres, CEO, CFO | S - Sale | $3.32 | -17,566 | 25,384 | -41% | -$58,402 | |||||
2026-09-21 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale | $95.75 | -533 | 14,219 | -4% | -$51,035 | ||||||
| D | 2026-09-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $50.35 | -6,018 | 38,000 | -14% | -$303,003 | |||||
| D | 2026-09-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | CHIEF MEDICAL OFFICER | S - Sale+OE | $50.35 | -5,000 | 25,000 | -17% | -$251,754 | |||||
| D | 2026-09-17 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | S - Sale+OE | $29.37 | -31,599 | 69,956 | -31% | -$927,970 | |||||
2026-09-21 | CYBN | Cybin Inc. | Halstead Michael | CEO | P - Purchase | $13.47 | +100,000 | 168,568 | +146% | +$1,347,050 | ||||||
| D | 2026-09-21 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | GC | S - Sale+OE | $93.64 | -10,000 | 29,995 | -25% | -$936,417 | |||||
| D | 2026-09-18 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $494.79 | -9,500 | 668,728 | -1% | -$4,700,505 | |||||
2026-09-18 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.43 | +100,000 | 1,062,500 | +10% | +$843,460 | ||||||
| D | 2026-09-17 | PHVS | Pharvaris N.V. | Lu Peng | Pres | S - Sale+OE | $35.00 | -100,000 | 64,953 | -61% | -$3,500,000 | |||||
2026-09-17 | PHVS | Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus | Dir | S - Sale | $35.00 | -200,000 | 115,167 | -63% | -$7,000,000 | ||||||
| D | 2026-09-18 | NBP | Novabridge Biosciences | Dennis Phillip Andrew | Chief Medical Officer | S - Sale+OE | $0.71 | -8,209 | 173,427 | -5% | -$5,828 | |||||
| D | 2026-09-17 | PHVS | Pharvaris N.V. | Bjork Elisabeth | Dir | S - Sale+OE | $37.89 | -52,500 | 15,167 | -78% | -$1,989,409 | |||||
| D | 2026-09-17 | PHVS | Pharvaris N.V. | Glassman Robert | Dir | S - Sale+OE | $38.56 | -14,493 | 10,500 | -58% | -$558,812 | |||||
2026-09-17 | PHVS | Pharvaris N.V. | Lesage Anne | Chief Early Development | S - Sale | $38.27 | -20,000 | 130,419 | -13% | -$765,466 | ||||||
2026-09-15 | NTHI | Neonc Technologies Holdings, Inc. | Garnett Keithly | CFO | S - Sale | $3.36 | -5,000 | 281,410 | -2% | -$16,809 | ||||||
2026-09-16 | CORT | Corcept Therapeutics Inc | Vieira Roberto Wandenkolk | Pres, Oncology | S - Sale | $100.82 | -296 | 3,946 | -7% | -$29,843 | ||||||
2026-09-16 | SKYE | Skye Bioscience, Inc. | Schwab Andrew J. | Dir, 10% | S - Sale | $1.91 | -33,892 | 1,129,348 | -3% | -$64,734 | ||||||
2026-09-16 | SKYE | Skye Bioscience, Inc. | 5Am Partners Vii, LLC | 10% | S - Sale | $1.91 | -33,892 | 1,129,348 | -3% | -$64,734 | ||||||
| M | 2026-09-16 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $67.49 | -20,000 | 1,459,860 | -1% | -$1,349,728 | |||||
| DM | 2026-09-16 | HRMY | Harmony Biosciences Holdings, Inc. | Budur Kumar | CHIEF MEDICAL OFFICER | S - Sale+OE | $43.05 | -38,452 | 13,115 | -75% | -$1,655,416 | |||||
| D | 2026-09-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $496.06 | -9,500 | 668,728 | -1% | -$4,712,580 | |||||
| D | 2026-09-17 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $497.54 | -8,300 | 45,172 | -16% | -$4,129,608 | |||||
| D | 2026-09-17 | DNTH | Dianthus Therapeutics, Inc. /De/ | Carr Edward | CHIEF ACCOUNTING OFFICER | S - Sale+OE | $101.38 | -20,000 | 0 | -100% | -$2,027,646 | |||||
2026-09-16 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $25.00 | -3,674 | 112,508 | -3% | -$91,853 | ||||||
2026-09-16 | MPLT | Maplight Therapeutics, Inc. | Hanson Kristopher | GC | S - Sale | $11.67 | -16,509 | 137,044 | -11% | -$192,660 | ||||||
| D | 2026-09-16 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale+OE | $16.33 | -12,394 | 39,900 | -24% | -$202,437 | |||||
| D | 2026-09-16 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $152.24 | -4,302 | 0 | -100% | -$654,923 | |||||
2026-09-16 | CBIO | Crescent Biopharma, Inc. | Lynch Ryan | See Remarks | S - Sale | $17.90 | -240 | 13,631 | -2% | -$4,296 | ||||||
2026-09-16 | CBIO | Crescent Biopharma, Inc. | Pinkas Jan | Chief Scientific Officer | S - Sale | $17.90 | -658 | 21,581 | -3% | -$11,778 | ||||||
2026-09-16 | CBIO | Crescent Biopharma, Inc. | Im Ellie Eunkyung | Chief Medical Officer | S - Sale | $17.90 | -623 | 21,446 | -3% | -$11,152 | ||||||
2026-09-16 | CBIO | Crescent Biopharma, Inc. | Scalzo Richard William | CFO | S - Sale | $17.90 | -568 | 19,730 | -3% | -$10,167 | ||||||
2026-09-16 | CBIO | Crescent Biopharma, Inc. | Bispham Barbara Harlin | See Remarks | S - Sale | $17.90 | -620 | 18,710 | -3% | -$11,098 | ||||||
| M | 2026-09-16 | CBIO | Crescent Biopharma, Inc. | Brumm Joshua T | CEO | S - Sale | $16.91 | -9,447 | 271,765 | -3% | -$159,775 | |||||
| M | 2026-09-16 | CBIO | Crescent Biopharma, Inc. | McNeill Jonathan | Pres, COO | S - Sale | $16.90 | -4,570 | 134,588 | -3% | -$77,235 | |||||
| DM | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | Rote William E. | Chief Research Officer | S - Sale+OE | $62.83 | -209,048 | 98,197 | -68% | -$13,135,397 | |||||
| DM | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | S - Sale+OE | $63.06 | -283,189 | 117,066 | -71% | -$17,857,830 | |||||
| D | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | EVP, Head of R, D, CMO | S - Sale+OE | $62.34 | -44,674 | 100,491 | -31% | -$2,785,021 | |||||
| D | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale+OE | $62.34 | -37,500 | 105,389 | -26% | -$2,337,695 | |||||
| DM | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO | S - Sale+OE | $63.48 | -400,000 | 432,886 | -48% | -$25,390,729 | |||||
| D | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale+OE | $62.34 | -50,508 | 87,508 | -37% | -$3,148,544 | |||||
| D | 2026-09-16 | TENX | Tenax Therapeutics, Inc. | Doogan Declan | Dir | P - Purchase | $1.92 | +53,000 | 55,274 | >999% | +$101,760 | |||||
| D | 2026-09-15 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, Chief Accounting Officer | S - Sale+OE | $62.33 | -5,375 | 42,353 | -11% | -$335,005 | |||||
2026-09-15 | ROIV | Roivant Sciences Ltd. | Epperly Melissa B, | Dir | S - Sale | $39.74 | -4,938 | 9,900 | -33% | -$196,230 | ||||||
2026-09-15 | ROIV | Roivant Sciences Ltd. | Fitzgerald Meghan | Dir | S - Sale | $39.74 | -5,112 | 36,108 | -12% | -$203,152 | ||||||
| D | 2026-09-16 | AMPH | Amphastar Pharmaceuticals, Inc. | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | S - Sale+OE | $23.94 | -10,000 | 273,871 | -4% | -$239,404 | |||||
2026-09-15 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | SVP, COMM, MEDICAL AFFAIRS | S - Sale | $17.03 | -13,314 | 213,476 | -6% | -$226,793 | ||||||
| D | 2026-09-15 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Dir | S - Sale+OE | $28.58 | -3,000 | 6,200 | -33% | -$85,740 | |||||
| D | 2026-09-15 | TRVI | Trevi Therapeutics, Inc. | Heffernan Michael Thomas | Dir | S - Sale+OE | $15.09 | -39,473 | 6,351 | -86% | -$595,806 | |||||
| D | 2026-09-16 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $501.39 | -9,500 | 668,728 | -1% | -$4,763,172 | |||||
| D | 2026-09-15 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale+OE | $37.00 | -18,500 | 235,244 | -7% | -$684,500 | |||||
2026-09-15 | CLYM | Climb Bio, Inc. | Thomas Stephen Basil | Dir | S - Sale | $13.67 | -100,000 | 467,969 | -18% | -$1,366,820 | ||||||
| D | 2026-09-15 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale+OE | $24.18 | -4,730 | 35,841 | -12% | -$114,371 | |||||
2026-09-16 | UPB | Upstream Bio, Inc. | Gray Michael | CFO, COO | S - Sale | $5.49 | -853 | 27,942 | -3% | -$4,683 | ||||||
2026-09-16 | UPB | Upstream Bio, Inc. | Ambrose Allison | GC | S - Sale | $5.49 | -485 | 15,563 | -3% | -$2,663 | ||||||
2026-09-15 | LFVN | Lifevantage Corp | Lewis Darwin | Dir | P - Purchase | $6.22 | +976 | 138,244 | +1% | +$6,071 | ||||||
2026-09-16 | UPB | Upstream Bio, Inc. | Deykin Aaron | Chief Medical Officer | S - Sale | $5.49 | -895 | 32,302 | -3% | -$4,914 | ||||||
2026-09-16 | UPB | Upstream Bio, Inc. | Sutherland Everett Rand | CEO | S - Sale | $5.49 | -2,095 | 68,717 | -3% | -$11,502 | ||||||
2026-09-16 | UPB | Upstream Bio, Inc. | Houghton Adam | Chief Business Officer | S - Sale | $5.49 | -700 | 22,901 | -3% | -$3,843 | ||||||
| D | 2026-09-15 | PHVS | Pharvaris N.V. | Abele Stefan Andreas | Chief Technical Ops Officer | S - Sale+OE | $38.17 | -46,400 | 39,068 | -54% | -$1,771,125 | |||||
2026-09-14 | KMDA | Kamada Ltd | Tsur David | Dir | S - Sale | $8.18 | -22,827 | 407,929 | -5% | -$186,725 | ||||||
| D | 2026-09-15 | PHVS | Pharvaris N.V. | Glassman Robert | Dir | S - Sale+OE | $38.27 | -8,667 | 10,500 | -45% | -$331,716 | |||||
2026-09-16 | ADAG | Adagene Inc. | Luo Peter | CEO | P - Purchase | $3.15 | +20,290 | 88,535 | +30% | +$63,980 | ||||||
2026-09-14 | PBYI | Puma Biotechnology, Inc. | Wilson Troy Edward | Dir | S - Sale | $9.10 | -5,000 | 55,300 | -8% | -$45,500 | ||||||
| D | 2026-09-14 | PBYI | Puma Biotechnology, Inc. | Cesano Alessandra | Dir | S - Sale+OE | $9.12 | -62,150 | 56,700 | -52% | -$566,994 | |||||
| M | 2026-09-14 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.30 | +91,101 | 892,101 | +11% | +$118,076 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |